### **POSTER PRESENTATION**



**Open Access** 

# MGBG–cisplatin combination chemotherapy against breast cancer

Raquel F Gonsalves<sup>1\*</sup>, Maria PM Marques<sup>1,2</sup>

*From* 16th International Charles Heidelberger Symposium on Cancer Research Coimbra, Portugal. 26–28 September 2010

Worldwide, it is estimated that more than one million women are diagnosed with breast cancer every year, representing 14% of female cancer deaths [1], about 4,500 new cases being detected each year in Portugal. In the present study, the compound metylglyoxal bis(guanylhydrazone) (MGBG) [2], an inhibitor of S-adenosyl-L-methionine descarboxylase (SAMdc), was investigated as a potencial anti-cancer agent towards the breast cancer cell line MCF-7 and the non-carcinogenic, nonimmortalized, human foreskin fibroblast cells BJ. The results (MTT assay) evidenced that the effect of MGBG against the MCF-7 cells is dose and time dependent, revealing a significant cell viability loss (ca. 90% at 72 h, for a 50 µM dosage). Since its effect was not shown to be reversible, this compound appears to be quite effective in this line. In fact, compared to cisplatin (cDDP), a commonly used drug in clinical practice, MGBG provided a larger cytotoxicity in the same concentration range. Similarly, a slight synergistic effect was verified for these two compounds - ca. 93% at 72 h, for an MGBG(50  $\mu$ M):CDDP(10  $\mu$ M) combination, while no effect was assessed on the reversibility of the cytotoxic action. Regarding the non-neoplastic BJ line, MBGB exhibited a clear reversibility of et growth-inhibiting effect, as opposed to cDDP and the MGBG:cDDP cocktails.

#### Author details

<sup>1</sup>"Molecular Physical-Chemistry" R&D Unit, University of Coimbra, Coimbra, Portugal. <sup>2</sup>Department of Life Sciences, Faculty of Sciences and Technology, University of Coimbra, Coimbra, Portugal.

#### Published: 24 September 2010

<sup>1</sup>"Molecular Physical-Chemistry" R&D Unit, University of Coimbra, Coimbra, Portugal

Full list of author information is available at the end of the article



© 2010 Gonsalves et al; licensee BioMed Central Ltd.

#### References

- 1. Coughlin SS, Ekwueme DU: Breast cancer as a global health concern. Cancer Epidemiol 2009, 33:315-318.
- Marques MPM, Gil FPSC, Calheiros R, Battaglia V, Brunati AM, Agostinelli E, Toninello A: Biological activity of antitumoural MGBG: the structural variable. Amino Acids 2008, 34:555-564.

#### doi:10.1016/j.canep.2009.10.003

**Cite this article as:** Gonsalves and Marques: **MGBG–cisplatin combination chemotherapy against breast cancer**. *BMC Proceedings* 2010 **4**(Suppl 2):P27.

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

) BioMed Central

<sup>\*</sup> Correspondence: raquel.fg7@gmail.com